Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 370

1.

Pinholes and presbyopia: solution or sideshow?

Charman WN.

Ophthalmic Physiol Opt. 2019 Jan;39(1):1-10. doi: 10.1111/opo.12594. No abstract available.

PMID:
30628739
2.

Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H3 receptor antagonists.

Riddy DM, Cook AE, Shackleford DM, Pierce TL, Mocaer E, Mannoury la Cour C, Sors A, Charman WN, Summers RJ, Sexton PM, Christopoulos A, Langmead CJ.

Neuropharmacology. 2019 Jan;144:244-255. doi: 10.1016/j.neuropharm.2018.10.028. Epub 2018 Oct 22.

PMID:
30359639
3.

Divergent effects of strontium and calcium-sensing receptor positive allosteric modulators (calcimimetics) on human osteoclast activity.

Diepenhorst NA, Leach K, Keller AN, Rueda P, Cook AE, Pierce TL, Nowell C, Pastoureau P, Sabatini M, Summers RJ, Charman WN, Sexton PM, Christopoulos A, Langmead CJ.

Br J Pharmacol. 2018 Nov;175(21):4095-4108. doi: 10.1111/bph.14344. Epub 2018 Jun 3.

PMID:
29714810
4.

Accommodation and age-dependent eye model based on in vivo measurements.

Zapata-Díaz JF, Radhakrishnan H, Charman WN, López-Gil N.

J Optom. 2019 Jan - Mar;12(1):3-13. doi: 10.1016/j.optom.2018.01.003. Epub 2018 Mar 21.

5.

Virtual Issue Editorial: Presbyopia - grappling with an age-old problem.

Charman WN.

Ophthalmic Physiol Opt. 2017 Nov;37(6):655-660. doi: 10.1111/opo.12416. No abstract available.

PMID:
29044672
6.

The role of lecithin degradation on the pH dependent stability of halofantrine encapsulated fat nano-emulsions.

Haidar I, Harding IH, Bowater IC, Eldridge DS, Charman WN.

Int J Pharm. 2017 Aug 7;528(1-2):524-535. doi: 10.1016/j.ijpharm.2017.06.040. Epub 2017 Jun 13.

PMID:
28619452
7.

Visual and Physiological Optics: where will the journey lead us in 10 years?

Rozema JJ, Charman WN, Atchison DA, Ginis H; VPO 2016 Scientific Committee and Delegates.

Ophthalmic Physiol Opt. 2017 May;37(3):235-239. doi: 10.1111/opo.12384. No abstract available.

PMID:
28439974
8.

Optical characteristics of Alvarez variable-power spectacles.

Radhakrishnan H, Charman WN.

Ophthalmic Physiol Opt. 2017 May;37(3):284-296. doi: 10.1111/opo.12361. Epub 2017 Feb 17.

PMID:
28211160
9.

Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).

Dong Y, Wang X, Kamaraj S, Bulbule VJ, Chiu FC, Chollet J, Dhanasekaran M, Hein CD, Papastogiannidis P, Morizzi J, Shackleford DM, Barker H, Ryan E, Scheurer C, Tang Y, Zhao Q, Zhou L, White KL, Urwyler H, Charman WN, Matile H, Wittlin S, Charman SA, Vennerstrom JL.

J Med Chem. 2017 Apr 13;60(7):2654-2668. doi: 10.1021/acs.jmedchem.6b01586. Epub 2017 Jan 18.

PMID:
28052200
10.

Correcting presbyopia: the problem of pupil size.

Charman WN.

Ophthalmic Physiol Opt. 2017 Jan;37(1):1-6. doi: 10.1111/opo.12346. No abstract available.

PMID:
28030880
11.

High throughput, quantitative analysis of human osteoclast differentiation and activity.

Diepenhorst NA, Nowell CJ, Rueda P, Henriksen K, Pierce T, Cook AE, Pastoureau P, Sabatini M, Charman WN, Christopoulos A, Summers RJ, Sexton PM, Langmead CJ.

Anal Biochem. 2017 Feb 15;519:51-56. doi: 10.1016/j.ab.2016.12.010. Epub 2016 Dec 14.

PMID:
27988276
12.

Isoform-Specific Biased Agonism of Histamine H3 Receptor Agonists.

Riddy DM, Cook AE, Diepenhorst NA, Bosnyak S, Brady R, Mannoury la Cour C, Mocaer E, Summers RJ, Charman WN, Sexton PM, Christopoulos A, Langmead CJ.

Mol Pharmacol. 2017 Feb;91(2):87-99. doi: 10.1124/mol.116.106153. Epub 2016 Nov 18. Erratum in: Mol Pharmacol. 2017 Mar;91(3):263.

PMID:
27864425
13.

François Pourfour du Petit (1664-1741): pioneer in ocular biometry.

Charman WN.

Ophthalmic Physiol Opt. 2016 Jul;36(4):428-38. doi: 10.1111/opo.12303. Epub 2016 May 15.

PMID:
27350184
14.

50years of oral lipid-based formulations: Provenance, progress and future perspectives.

Feeney OM, Crum MF, McEvoy CL, Trevaskis NL, Williams HD, Pouton CW, Charman WN, Bergström CAS, Porter CJH.

Adv Drug Deliv Rev. 2016 Jun 1;101:167-194. doi: 10.1016/j.addr.2016.04.007. Epub 2016 Apr 16. Review.

PMID:
27089810
15.

Computational prediction of formulation strategies for beyond-rule-of-5 compounds.

Bergström CAS, Charman WN, Porter CJH.

Adv Drug Deliv Rev. 2016 Jun 1;101:6-21. doi: 10.1016/j.addr.2016.02.005. Epub 2016 Feb 27. Review.

16.

Murine GPRC6A Mediates Cellular Responses to L-Amino Acids, but Not Osteocalcin Variants.

Rueda P, Harley E, Lu Y, Stewart GD, Fabb S, Diepenhorst N, Cremers B, Rouillon MH, Wehrle I, Geant A, Lamarche G, Leach K, Charman WN, Christopoulos A, Summers RJ, Sexton PM, Langmead CJ.

PLoS One. 2016 Jan 19;11(1):e0146846. doi: 10.1371/journal.pone.0146846. eCollection 2016.

17.

Do small-aperture presbyopic corrections influence the visual field?

Atchison DA, Blazaki S, Suheimat M, Plainis S, Charman WN.

Ophthalmic Physiol Opt. 2016 Jan;36(1):51-9. doi: 10.1111/opo.12265.

PMID:
26769327
18.

Presbyopia: physiology, prevention and pathways to correction.

Davies LN, Croft MA, Papas E, Charman WN.

Ophthalmic Physiol Opt. 2016 Jan;36(1):1-4. doi: 10.1111/opo.12272. No abstract available.

PMID:
26769325
19.

Myopia revisited, 2010-2015.

Charman WN.

Ophthalmic Physiol Opt. 2015 Nov;35(6):637-42. doi: 10.1111/opo.12259. No abstract available.

PMID:
26497297
20.

Accommodation response to Chinese and Latin characters in Chinese-illiterate young adults.

Radhakrishnan H, Hartwig A, Charman WN, Llorente L.

Clin Exp Optom. 2015 Nov;98(6):527-34. doi: 10.1111/cxo.12296. Epub 2015 Oct 8.

21.

Microfluctuations in accommodation: an update on their characteristics and possible role.

Charman WN, Heron G.

Ophthalmic Physiol Opt. 2015 Sep;35(5):476-99. doi: 10.1111/opo.12234. Review.

PMID:
26303445
22.

Label-Free Kinetics: Exploiting Functional Hemi-Equilibrium to Derive Rate Constants for Muscarinic Receptor Antagonists.

Riddy DM, Valant C, Rueda P, Charman WN, Sexton PM, Summers RJ, Christopoulos A, Langmead CJ.

Mol Pharmacol. 2015 Oct;88(4):779-90. doi: 10.1124/mol.115.100545. Epub 2015 Aug 4.

PMID:
26243731
23.

Baseline peripheral refractive error and changes in axial refraction during one year in a young adult population.

Hartwig A, Charman WN, Radhakrishnan H.

J Optom. 2016 Jan-Mar;9(1):32-9. doi: 10.1016/j.optom.2015.06.001. Epub 2015 Jul 16.

24.

Problems in comparisons of data for the prevalence of myopia and the frequency distribution of ametropia.

Plainis S, Charman WN.

Ophthalmic Physiol Opt. 2015 Jul;35(4):394-404. doi: 10.1111/opo.12214. Epub 2015 May 10.

PMID:
25959139
25.

The effect of testing distance on intraocular lens power calculation.

Simpson MJ, Charman WN.

J Refract Surg. 2014 Nov;30(11):726. doi: 10.3928/1081597X-20141021-01. No abstract available.

PMID:
25375842
26.

Visual field coordinates of pupillary circular axis and optical axis.

Atchison DA, Mathur A, Suheimat M, Charman WN.

Optom Vis Sci. 2014 May;91(5):582-7. doi: 10.1097/OPX.0000000000000228.

PMID:
24727827
27.

Developments in the correction of presbyopia II: surgical approaches.

Charman WN.

Ophthalmic Physiol Opt. 2014 Jul;34(4):397-426. doi: 10.1111/opo.12129. Epub 2014 Apr 10. Review.

PMID:
24716827
28.

Synthesis, structure-activity relationships and brain uptake of a novel series of benzopyran inhibitors of insulin-regulated aminopeptidase.

Mountford SJ, Albiston AL, Charman WN, Ng L, Holien JK, Parker MW, Nicolazzo JA, Thompson PE, Chai SY.

J Med Chem. 2014 Feb 27;57(4):1368-77. doi: 10.1021/jm401540f. Epub 2014 Feb 7.

PMID:
24471437
29.

Age-dependence of the average and equivalent refractive indices of the crystalline lens.

Charman WN, Atchison DA.

Biomed Opt Express. 2013 Dec 2;5(1):31-9. doi: 10.1364/BOE.5.000031. eCollection 2013 Dec 2.

30.

Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies.

Han S, Quach T, Hu L, Wahab A, Charman WN, Stella VJ, Trevaskis NL, Simpson JS, Porter CJ.

J Control Release. 2014 Mar 10;177:1-10. doi: 10.1016/j.jconrel.2013.12.031. Epub 2014 Jan 5.

PMID:
24398334
31.

Influence of stop position on spectacle magnification.

Atchison DA, Charman WN.

Optom Vis Sci. 2014 Jan;91(1):97-102. doi: 10.1097/OPX.0000000000000124.

PMID:
24270640
32.

Developments in the correction of presbyopia I: spectacle and contact lenses.

Charman WN.

Ophthalmic Physiol Opt. 2014 Jan;34(1):8-29. doi: 10.1111/opo.12091. Epub 2013 Nov 10. Review.

PMID:
24205890
33.

Small-aperture monovision and the Pulfrich experience: absence of neural adaptation effects.

Plainis S, Petratou D, Giannakopoulou T, Radhakrishnan H, Pallikaris IG, Charman WN.

PLoS One. 2013 Oct 14;8(10):e75987. doi: 10.1371/journal.pone.0075987. eCollection 2013.

34.

Winners in the 2012 Naylor prize competition.

Charman WN, Heron G, Whiteley A.

Ophthalmic Physiol Opt. 2013 Nov;33(6):675-6. doi: 10.1111/opo.12089. No abstract available.

PMID:
24118037
35.

Power profiles of multifocal contact lenses and their interpretation.

Plainis S, Atchison DA, Charman WN.

Optom Vis Sci. 2013 Oct;90(10):1066-77. doi: 10.1097/OPX.0000000000000030.

PMID:
23995515
36.

Binocular saccades in myopes and emmetropes.

Hartwig A, Gowen E, Charman WN, Radhakrishnan H.

Optom Vis Sci. 2013 Sep;90(9):980-7. doi: 10.1097/OPX.0000000000000015.

PMID:
23912966
37.

Computational prediction of drug solubility in lipid based formulation excipients.

Persson LC, Porter CJ, Charman WN, Bergström CA.

Pharm Res. 2013 Dec;30(12):3225-37. doi: 10.1007/s11095-013-1083-7. Epub 2013 Jun 15.

38.

Intestinal bile secretion promotes drug absorption from lipid colloidal phases via induction of supersaturation.

Yeap YY, Trevaskis NL, Quach T, Tso P, Charman WN, Porter CJ.

Mol Pharm. 2013 May 6;10(5):1874-89. doi: 10.1021/mp3006566. Epub 2013 Mar 27.

PMID:
23480483
39.

A mouse model to evaluate the impact of species, sex, and lipid load on lymphatic drug transport.

Trevaskis NL, Caliph SM, Nguyen G, Tso P, Charman WN, Porter CJ.

Pharm Res. 2013 Dec;30(12):3254-70. doi: 10.1007/s11095-013-1000-0. Epub 2013 Feb 21.

40.

Strategies to address low drug solubility in discovery and development.

Williams HD, Trevaskis NL, Charman SA, Shanker RM, Charman WN, Pouton CW, Porter CJ.

Pharmacol Rev. 2013 Jan;65(1):315-499. Review.

PMID:
23383426
41.

Short-term stability in refractive status despite large fluctuations in glucose levels in diabetes mellitus type 1 and 2.

Huntjens B, Charman WN, Workman H, Hosking SL, O'Donnell C.

PLoS One. 2012;7(12):e52947. doi: 10.1371/journal.pone.0052947. Epub 2012 Dec 28.

42.

Interocular differences in visual latency induced by reduced-aperture monovision.

Plainis S, Petratou D, Giannakopoulou T, Radhakrishnan H, Pallikaris IG, Charman WN.

Ophthalmic Physiol Opt. 2013 Mar;33(2):123-9. doi: 10.1111/opo.12018. Epub 2012 Dec 28.

PMID:
23278194
43.

Gradients of refractive index in the crystalline lens and transient changes in refraction among patients with diabetes.

Charman WN, Adnan, Atchison DA.

Biomed Opt Express. 2012 Dec 1;3(12):3033-42. doi: 10.1364/BOE.3.003033. Epub 2012 Oct 31.

44.

Through-focus performance with multifocal contact lenses: effect of binocularity, pupil diameter and inherent ocular aberrations.

Plainis S, Ntzilepis G, Atchison DA, Charman WN.

Ophthalmic Physiol Opt. 2013 Jan;33(1):42-50. doi: 10.1111/opo.12004. Epub 2012 Dec 1.

PMID:
23199097
45.

Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target.

Yuthavong Y, Tarnchompoo B, Vilaivan T, Chitnumsub P, Kamchonwongpaisan S, Charman SA, McLennan DN, White KL, Vivas L, Bongard E, Thongphanchang C, Taweechai S, Vanichtanankul J, Rattanajak R, Arwon U, Fantauzzi P, Yuvaniyama J, Charman WN, Matthews D.

Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):16823-8. doi: 10.1073/pnas.1204556109. Epub 2012 Oct 3.

46.

Optical modelling of the possible origins of transient refractive changes in diabetic patients.

Charman WN.

Ophthalmic Physiol Opt. 2012 Nov;32(6):485-91. doi: 10.1111/j.1475-1313.2012.00935.x. Epub 2012 Sep 7.

PMID:
22958271
47.

Antimalarial activity of pyrroloiminoquinones from the Australian marine sponge Zyzzya sp.

Davis RA, Buchanan MS, Duffy S, Avery VM, Charman SA, Charman WN, White KL, Shackleford DM, Edstein MD, Andrews KT, Camp D, Quinn RJ.

J Med Chem. 2012 Jun 28;55(12):5851-8. doi: 10.1021/jm3002795. Epub 2012 Jun 20.

PMID:
22686608
48.

Intravenous dosing conditions may affect systemic clearance for highly lipophilic drugs: implications for lymphatic transport and absolute bioavailability studies.

Caliph SM, Trevaskis NL, Charman WN, Porter CJ.

J Pharm Sci. 2012 Sep;101(9):3540-6. doi: 10.1002/jps.23211. Epub 2012 May 23.

PMID:
22623170
49.

Specifying peripheral aberrations in visual science.

Charman WN, Mathur A, Scott DH, Hartwig A, Atchison DA.

J Biomed Opt. 2012 Feb;17(2):025004. doi: 10.1117/1.JBO.17.2.025004.

PMID:
22463030
50.

Visual function through 4 contact lens-based pinhole systems for presbyopia.

García-Lázaro S, Ferrer-Blasco T, Radhakrishnan H, Cerviño A, Charman WN, Montés-Micó R.

J Cataract Refract Surg. 2012 May;38(5):858-65. doi: 10.1016/j.jcrs.2011.11.042. Epub 2012 Mar 16.

PMID:
22424803

Supplemental Content

Loading ...
Support Center